Positions

Overview

  • Aman Wadhwa, MD MSPH is a pediatric hematologist and oncologist whose research interests are rooted in understanding factors that increase morbidity and mortality among survivors of cancer as well as blood and marrow transplantation (BMT).

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2023 Body mass index during maintenance therapy and relapse risk in children with acute lymphoblastic leukemia: A Children's Oncology Group report.  Cancer.  129:151-160. 2023
    2022 Association between body composition and chemotherapy-related toxicity in children with lymphoma and rhabdomyosarcoma.  Cancer.  128:1302-1311. 2022
    2022 Burden of Morbidity after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A BMT Survivor Study Report 2022
    2022 Retrospective Application of Sinusoidal Obstruction Syndrome/Veno-occlusive Disease Diagnostic Criteria in a Pediatric Hematopoietic Stem Cell Transplant Cohort.  Journal of Pediatric Hematology/Oncology.  44:E343-E348. 2022
    2022 Filgrastim desensitization in a patient with Hodgkin lymphoma.  Pediatric Blood and Cancer.  69. 2022
    2022 Time to Antibiotic for Pediatric Oncology Patients with Febrile Neutropenia at Regional Emergency Departments.  Pediatric Emergency Care.  38:E94-E99. 2022
    2021 Metastatic pediatric sclerosing epithelioid fibrosarcoma.  Cold Spring Harbor molecular case studies.  7. 2021
    2019 Providing health care for patients with childhood cancer and survivors: A survey of pediatric primary care providers.  Cancer.  125:3864-3872. 2019
    2019 Late Mortality after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A Report from the Blood or Marrow Transplant Survivor Study-2 (BMTSS-2).  Biology of Blood and Marrow Transplantation.  25:328-334. 2019
    2018 Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood.  JAMA Oncology.  4. 2018
    2018 Blinatumomab activity in a patient with Down syndrome B-precursor acute lymphoblastic leukemia.  Pediatric Blood and Cancer.  65. 2018

    Research Overview

  • i) understanding the role played by obesity and body composition in toxicity from chemotherapy and survival in children with cancer,
    ii) understanding the burden of chronic health conditions in survivors of BMT performed during childhood and
    iii) investigating the role played by social determinants of health in explaining disparities in morbidity and mortality among BMT survivors.

    • Principal Investigator On

    Investigator On

  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Phase I/II Study of Bosutinib in Pediatric Patients with Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph+ Chronic Myeloid Leukemia, Study ITCC-054/COG AAML1921  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • AADVL18P1 – An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation”,  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • AALL 1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2- Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Lukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1331 - Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467,NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • AALL1931 - An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coll-Derived Asparaginases  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AAML1831A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations”  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • ADVL1712: A Phase I Trial of Pevonedistat Given in Combination with Fludarabine, Cytarabine, and Azacitidine in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AHOD1721, Risk-based, Response-Adapted, Phase ll Open- Label Trail of Nivolumab+Brentuximab Vedotin(N+Bv) for Children,Adolescents, and Young Adults with Relapsed/ Refractory (R/R) CD30+ Classic Hodgkin Lymphoma (cHL) after Failure of First -Line Therapy, followed by Brentuximab+Bendamustine(Bv+B) for participants with a suboptimal response;CheckMate 744:Checkpoint Pathway and Nivolumab Clinical Trail Evaluation.  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AHOD1822 -- AnOpen-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • An Open-Label, Multi-Center Phase 1/2 study of Surufatinib in Combination with Gemcitabine in Pediatric Patients with Recurrent or Refractory Solid Tumors COG ADVL2121  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Body Composition and Adverse Outcomes in Childhood Cancer  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE
  • Body Composition and Outcomes in Childhood Cancer  awarded by St. Baldrick's Foundation
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • L-12610 Pilot Study Using Induction Chemo-Immunotherapy Followed by Consolidation with Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-Anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults  awarded by NEW YORK MEDICAL COLLEGE
  • Larotrectinib for Previously Untreated NTRK-fusion Positive Pediatric Solid Tumors and NTRK-fusion Positive Relapsed Pediatric Acute Leukemias, COG ID ADVL1823  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • PEPCTN1812 - A Phase 1 Trial of the CD123 X CD3 Dual Affinity Re-Targeting Antibody Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • PEPN2111- A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma,  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • PEPN2112- A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • PER CASE REIMBURSEMENT NCORP Operations Grant 7UG1CA189955 -PHI/COG  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Per Case Reimbursement (PCR)- NIH National Clinical Trails Network (NCTN) Grant (U10CA180886) -PHI/COG  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Per Case Reimbursement - NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) - PHI/COG  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Per Case Reimbursement COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by Genentech
  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)

    • Education And Training

  • Bachelor of Medicine & Surgery (MBBS), Rajiv Gandhi University of Health Sciences 2012

    • Full Name

  • Aman Wadhwa